JP2005504043A - 生物学的に活性な金属ペプチド類のペプチド模倣体類 - Google Patents
生物学的に活性な金属ペプチド類のペプチド模倣体類 Download PDFInfo
- Publication number
- JP2005504043A JP2005504043A JP2003518577A JP2003518577A JP2005504043A JP 2005504043 A JP2005504043 A JP 2005504043A JP 2003518577 A JP2003518577 A JP 2003518577A JP 2003518577 A JP2003518577 A JP 2003518577A JP 2005504043 A JP2005504043 A JP 2005504043A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- amino acid
- peptidomimetic
- phe
- biologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCCCNC1=N*C=C1 Chemical compound CCCCNC1=N*C=C1 0.000 description 18
- CJFYRIGZUUSDRP-CABCVRRESA-N CN(C[C@@H](C1)OCc2ccccc2)[C@@H]1C(NCCCN)=O Chemical compound CN(C[C@@H](C1)OCc2ccccc2)[C@@H]1C(NCCCN)=O CJFYRIGZUUSDRP-CABCVRRESA-N 0.000 description 3
- AZTYQGRICHZESB-UHFFFAOYSA-N CCCCCNC(CC1CCCCC1)=O Chemical compound CCCCCNC(CC1CCCCC1)=O AZTYQGRICHZESB-UHFFFAOYSA-N 0.000 description 2
- CEKBEHDMMVWFNC-UHFFFAOYSA-N CCCCNc1nnc[s]1 Chemical compound CCCCNc1nnc[s]1 CEKBEHDMMVWFNC-UHFFFAOYSA-N 0.000 description 2
- SPVDPKLTNMQHNW-MVGXFMOLSA-N CN([C@H]1CCCNC(N)=N)C(CC[C@@H]2COc3ccc(cccc4)c4c3)N2C1=O Chemical compound CN([C@H]1CCCNC(N)=N)C(CC[C@@H]2COc3ccc(cccc4)c4c3)N2C1=O SPVDPKLTNMQHNW-MVGXFMOLSA-N 0.000 description 2
- MVFSHJDMJHIIOO-FQEVSTJZSA-N C=CN(CCN1CCc2cc(cccc3)c3cc2)[C@@H](CCCN)C1=O Chemical compound C=CN(CCN1CCc2cc(cccc3)c3cc2)[C@@H](CCCN)C1=O MVFSHJDMJHIIOO-FQEVSTJZSA-N 0.000 description 1
- IDGHYDUKILPPNG-UHFFFAOYSA-N CCCCCNC(c(cc1)ccc1O)=O Chemical compound CCCCCNC(c(cc1)ccc1O)=O IDGHYDUKILPPNG-UHFFFAOYSA-N 0.000 description 1
- JPMLYRVKENTHQW-UHFFFAOYSA-N CCCCCNC(c(cc1)ccc1O)O Chemical compound CCCCCNC(c(cc1)ccc1O)O JPMLYRVKENTHQW-UHFFFAOYSA-N 0.000 description 1
- LZDRLYMZVCFDSN-UHFFFAOYSA-N CCCCCNC(c1ccccc1)=O Chemical compound CCCCCNC(c1ccccc1)=O LZDRLYMZVCFDSN-UHFFFAOYSA-N 0.000 description 1
- JDCDOJMYHQCEQZ-UHFFFAOYSA-N CCCCCNC(c1cccnc1)=O Chemical compound CCCCCNC(c1cccnc1)=O JDCDOJMYHQCEQZ-UHFFFAOYSA-N 0.000 description 1
- RQSQDLMCBYNAMB-UHFFFAOYSA-N CCCCNc1n[nH]cc1 Chemical compound CCCCNc1n[nH]cc1 RQSQDLMCBYNAMB-UHFFFAOYSA-N 0.000 description 1
- HSSUQMDTTMMOGQ-UHFFFAOYSA-N CCCCNc1ncccn1 Chemical compound CCCCNc1ncccn1 HSSUQMDTTMMOGQ-UHFFFAOYSA-N 0.000 description 1
- NSGZEKTXHYHICN-UHFFFAOYSA-N CCCC[n]1ncnc1 Chemical compound CCCC[n]1ncnc1 NSGZEKTXHYHICN-UHFFFAOYSA-N 0.000 description 1
- XYFUFGBKLWZBRS-SFHVURJKSA-N CCN(CCN1CCc2c[nH]c3c2cccc3)[C@@H](CCCNC(N)=N)C1=O Chemical compound CCN(CCN1CCc2c[nH]c3c2cccc3)[C@@H](CCCNC(N)=N)C1=O XYFUFGBKLWZBRS-SFHVURJKSA-N 0.000 description 1
- LCOVNDKIRVQZLT-DOYJUQJDSA-N CCN([C@H]1CCCCN)C(CC[C@@H]2COc3cc(cccc4)c4cc3)N2C1=O Chemical compound CCN([C@H]1CCCCN)C(CC[C@@H]2COc3cc(cccc4)c4cc3)N2C1=O LCOVNDKIRVQZLT-DOYJUQJDSA-N 0.000 description 1
- ZLCBAJFIKVAECA-LGWYJFNUSA-N CCN([C@H]1CCCNC(N)=N)C(CC[C@@H]2COc3cc(cccc4)c4cc3)N2C1=O Chemical compound CCN([C@H]1CCCNC(N)=N)C(CC[C@@H]2COc3cc(cccc4)c4cc3)N2C1=O ZLCBAJFIKVAECA-LGWYJFNUSA-N 0.000 description 1
- CJFYRIGZUUSDRP-LOACHALJSA-N CN(CC(C1)OCc2ccccc2)[C@@H]1C(NCCCN)=O Chemical compound CN(CC(C1)OCc2ccccc2)[C@@H]1C(NCCCN)=O CJFYRIGZUUSDRP-LOACHALJSA-N 0.000 description 1
- OAOUKXFUEJBGMF-NEPJUHHUSA-N CN(C[C@@H](C1)OCc2ccccc2)[C@@H]1C(N)=O Chemical compound CN(C[C@@H](C1)OCc2ccccc2)[C@@H]1C(N)=O OAOUKXFUEJBGMF-NEPJUHHUSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31140401P | 2001-08-10 | 2001-08-10 | |
PCT/US2002/025574 WO2003013571A1 (en) | 2001-08-10 | 2002-08-12 | Peptidomimetics of biologically active metallopeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2005504043A true JP2005504043A (ja) | 2005-02-10 |
Family
ID=23206723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003518577A Pending JP2005504043A (ja) | 2001-08-10 | 2002-08-12 | 生物学的に活性な金属ペプチド類のペプチド模倣体類 |
Country Status (6)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010523722A (ja) * | 2007-04-13 | 2010-07-15 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ジアゾ二環式smac模倣物およびその使用 |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7732451B2 (en) * | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
US7456184B2 (en) * | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
US7655658B2 (en) * | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
CA2462200A1 (en) * | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
BR0307279A (pt) * | 2002-01-29 | 2004-12-28 | Wyeth Corp | Métodos para fechar e abrir um semi-canal e uma célula, tecido orgãnico ou órgão, para prevenir ou tratar o estresse de tecido orgãnico ou órgão em um mamìfero, para aumentar a comunicação intracelular da junção com intervalo em uma célula, tecido orgãnico ou órgão, para tratamento de queimaduras, de tromboses, da acidose respitatória e metabólica, e da arritmia focal, para tratar e prevenir o dano de célula e tecido orgãnico resultante de nìveis elevados de glicose no sangue, para tratamento da fibrilação atrial crÈnica e da epilepsia, para criar composto candidatos que modulem a função de semi-canal, para citoproteger tecido orgãnico ou um órgão de um mamìfero em necessidade de tal tratamento, e para prevenir ou tratar o dano da reperfusão em um mamìfero |
US7026335B2 (en) | 2002-04-30 | 2006-04-11 | The Procter & Gamble Co. | Melanocortin receptor ligands |
TW200504033A (en) | 2002-10-23 | 2005-02-01 | Procter & Gamble | Melanocortin receptor ligands |
US7968548B2 (en) * | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
WO2005102340A1 (en) * | 2003-05-30 | 2005-11-03 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
WO2005079574A1 (en) * | 2004-01-21 | 2005-09-01 | Palatin Technologies, Inc. | Bicyclic melanocorin-specific compounds |
US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
EP1688161A1 (en) * | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
WO2006081276A1 (en) * | 2005-01-26 | 2006-08-03 | Allergan, Inc. | 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimulant activity |
US20070129444A1 (en) * | 2005-12-06 | 2007-06-07 | Mallinckrodt Inc. | Novel weight reduction composition and uses thereof |
NZ569293A (en) | 2005-12-23 | 2011-10-28 | Zealand Pharma As | Modified lysine-mimetic compounds |
US7951823B2 (en) | 2006-05-23 | 2011-05-31 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
RU2009108280A (ru) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение |
US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
ATE493174T1 (de) * | 2007-01-10 | 2011-01-15 | Irm Llc | Verbindungen und zusammensetzungen als kanal- aktivierende proteasehemmer |
WO2008090357A2 (en) * | 2007-01-24 | 2008-07-31 | Palatin Technologies, Inc. | N, n; -substituted piperazines binding to melanocortin receptor |
US20090076029A1 (en) * | 2007-06-01 | 2009-03-19 | Palatin Technologies, Inc. | Compounds and Methods for Treating Obesity |
US20090081197A1 (en) * | 2007-06-01 | 2009-03-26 | Palatin Technologies, Inc. | Methods for Selection of Melanocortin Receptor-Specific Agents for Treatment of Obesity |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8008291B2 (en) | 2008-02-29 | 2011-08-30 | Mimetica Pty Ltd | 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists |
US8440653B2 (en) * | 2008-02-29 | 2013-05-14 | Mimetica Pty Ltd | 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists |
EP2300032A4 (en) | 2008-05-13 | 2012-12-05 | Univ Kansas | MARKER PRESENTING IN THE FORM OF A MAP PEPTIDE (METAL ABSTRACTION PEPTIDE) AND ASSOCIATED METHODS |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
CA2743489A1 (en) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
UY32690A (es) * | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011011508A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
NZ599774A (en) * | 2009-11-23 | 2014-11-28 | Palatin Technologies Inc | Melanocortin-1 receptor-specific cyclic peptides |
AR079451A1 (es) | 2009-12-18 | 2012-01-25 | Nycomed Gmbh | Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina |
WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
EP2568812B1 (en) | 2010-05-11 | 2016-10-26 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
WO2011156246A1 (en) | 2010-06-11 | 2011-12-15 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
MX2013004906A (es) | 2010-11-01 | 2013-12-06 | Genoscience Pharma | Nuevos inhibidores especificos de la proteasa ns3 de hcv. |
EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
MX339762B (es) * | 2011-09-28 | 2016-05-27 | Univ Autonoma Del Estado De Morelos | Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen. |
WO2013067309A1 (en) | 2011-11-04 | 2013-05-10 | Xion Pharmaceutical Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
WO2013106689A1 (en) | 2012-01-12 | 2013-07-18 | Ref Pharma, Llc. | Hcv ns3 protease inhibitors |
WO2013181461A2 (en) | 2012-06-01 | 2013-12-05 | University Of Kansas | Metal abstraction peptide with superoxide dismutase activity |
WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
GB201521903D0 (en) | 2015-12-11 | 2016-01-27 | Electrophoretics Ltd | Isorbaric mass labels |
WO2018202865A1 (en) | 2017-05-05 | 2018-11-08 | Zealand Pharma A/S | Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease |
CN110981936B (zh) * | 2018-09-28 | 2021-10-12 | 北京京东方技术开发有限公司 | 类肽化合物及其制备方法、寡聚物、药物组合物和试剂盒 |
Family Cites Families (183)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4148923A (en) | 1972-05-31 | 1979-04-10 | Synthelabo | 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity |
US4626549A (en) | 1974-01-10 | 1986-12-02 | Eli Lilly And Company | Treatment of obesity with aryloxyphenylpropylamines |
IT1157365B (it) | 1977-10-24 | 1987-02-11 | Sandoz Ag | Medicamenti per trattare l'obesita' o ridurre il peso del corpo |
US4711957A (en) | 1979-07-13 | 1987-12-08 | The B. F. Goodrich Company | Synthesis of 2-keto-1,4-diazacycloalkanes |
US4434454A (en) * | 1981-02-06 | 1984-02-28 | Day J Michael | Active lighting system including light control keyboard |
US4766125A (en) * | 1981-06-23 | 1988-08-23 | Janssen Pharmaceutica N.V. | N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia |
US4680289A (en) | 1985-06-05 | 1987-07-14 | Progenics, Inc. | Treatment of obesity and diabetes using sapogenins |
GB8607312D0 (en) | 1986-03-25 | 1986-04-30 | Ici Plc | Therapeutic agents |
US4968684A (en) | 1987-04-01 | 1990-11-06 | Janssen Pharmaceutica N.V. | Method of improving sleep |
DK247789A (da) * | 1988-05-23 | 1989-11-24 | Glaxo Group Ltd | Piperazinderivater |
US4938763B1 (en) * | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US4997836A (en) * | 1988-11-11 | 1991-03-05 | Takeda Chemical Industries, Ltd. | Trisubstituted piperazine compounds, their production and use |
US5120713A (en) | 1990-09-10 | 1992-06-09 | Applied Research Systems Ars Holding N.V. | Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide |
US5331573A (en) * | 1990-12-14 | 1994-07-19 | Balaji Vitukudi N | Method of design of compounds that mimic conformational features of selected peptides |
US5292726A (en) * | 1991-05-22 | 1994-03-08 | Merck & Co., Inc. | N,N-diacylpiperazines |
SE9202266D0 (sv) | 1992-07-31 | 1992-07-31 | Kabi Pharmacia Ab | Novel piperazine carboxamides |
US5432691A (en) * | 1992-11-18 | 1995-07-11 | Vari-Lite, Inc. | Automated truss module with deployment mechanism |
US5344830A (en) | 1992-12-10 | 1994-09-06 | Merck & Co., Inc. | N,N-diacylpiperazine tachykinin antagonists |
EP0690843B1 (en) | 1993-03-25 | 2000-08-30 | PHARMACIA & UPJOHN COMPANY | Formyl- or cyano- substituted indole derivatives having dopaminergic activity |
HUT70045A (en) | 1993-06-17 | 1995-09-28 | Takeda Chemical Industries Ltd | 2-piperazinone derivatives parmaceutical compositions containing them and process for producing them |
JPH09500109A (ja) * | 1993-06-18 | 1997-01-07 | メルク エンド カンパニー インコーポレーテッド | ファルネシル蛋白質トランスフェラーゼの阻害剤 |
US5348955A (en) | 1993-06-22 | 1994-09-20 | Merck & Co., Inc. | N,N-diacylpiperazines |
US5494919A (en) * | 1993-11-09 | 1996-02-27 | Merck & Co., Inc. | 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
US5721251A (en) * | 1993-12-10 | 1998-02-24 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
US5721250A (en) * | 1993-12-23 | 1998-02-24 | Merck & Co. Inc. | Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
US5599809A (en) * | 1994-09-29 | 1997-02-04 | Merck & Co., Inc. | Method for improving reproductive efficiency in farm animals |
US6245764B1 (en) * | 1995-03-24 | 2001-06-12 | Molecumetics Ltd. | β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins |
US5856326A (en) * | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
ATE277021T1 (de) | 1995-04-13 | 2004-10-15 | Aventis Pharma Inc | Neue substituierte piperazinderivate mit tachykininrezeptor-antagonistischer wirkung |
WO1996033982A1 (en) * | 1995-04-26 | 1996-10-31 | Takeda Chemical Industries, Ltd. | Piperazinones useful as inhibitors of platelet aggregation |
US5719156A (en) * | 1995-05-02 | 1998-02-17 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
ES2235171T3 (es) * | 1995-05-29 | 2005-07-01 | Pfizer Inc. | Dipeptidos que promueven la liberacion de la hormona de crecimiento. |
DE19518988A1 (de) | 1995-05-29 | 1996-12-05 | Basf Ag | Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit |
US5891418A (en) * | 1995-06-07 | 1999-04-06 | Rhomed Incorporated | Peptide-metal ion pharmaceutical constructs and applications |
US6027711A (en) * | 1995-06-07 | 2000-02-22 | Rhomed Incorporated | Structurally determined metallo-constructs and applications |
US6184223B1 (en) * | 1995-10-27 | 2001-02-06 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
US5753653A (en) * | 1995-12-08 | 1998-05-19 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
AU714931B2 (en) * | 1995-12-18 | 2000-01-13 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives as tachykinin antagonists |
US5763445A (en) * | 1996-03-08 | 1998-06-09 | Adolor Corporation | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
US6239154B1 (en) | 1996-03-08 | 2001-05-29 | Adolor Corporation | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
US6303611B1 (en) | 1996-03-08 | 2001-10-16 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
GB9612276D0 (en) | 1996-06-12 | 1996-08-14 | Merck & Co Inc | 4-Spiroindoline piperidines promote release of growth hormone |
US5804578A (en) | 1996-04-03 | 1998-09-08 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
US5880128A (en) * | 1996-05-08 | 1999-03-09 | Schering Corporation | Carbonyl piperazinyl and piperidinyl compounds |
GB9611461D0 (en) * | 1996-06-01 | 1996-08-07 | Ciba Geigy Ag | New compounds |
US6331285B1 (en) | 1996-06-05 | 2001-12-18 | Palatin Technologies, Inc. | Structurally determined cyclic metallo-constructs and applications |
US5998421A (en) | 1996-06-12 | 1999-12-07 | Kyowa Hakko Kogyo Co., Ltd. | Lipid metabolism ameliorants |
US5877182A (en) | 1996-09-13 | 1999-03-02 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
AU4342097A (en) | 1996-09-13 | 1998-04-02 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone |
WO1998017625A1 (fr) * | 1996-10-22 | 1998-04-30 | Daiichi Pharmaceutical Co., Ltd. | Nouveaux remedes pour des maladies infectieuses |
US5734054A (en) * | 1996-11-05 | 1998-03-31 | Pharmacopeia, Inc. | Hydroxy-amino acid amides |
US5965565A (en) | 1996-12-12 | 1999-10-12 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
KR20000057595A (ko) * | 1996-12-17 | 2000-09-25 | 후지야마 아키라 | Mmp 또는 tnf의 억제제로서 피페라진 화합물 |
DE69705746T2 (de) * | 1996-12-20 | 2001-10-31 | Alza Corp | Injizierbare depotgelzubereitung und herstellungsverfahren |
US6162805A (en) | 1997-04-24 | 2000-12-19 | Merck Sharp & Dohme Limited | Use of an NK-1 receptor antagonist and an SSRI for treating obesity |
KR100467058B1 (ko) | 1997-05-27 | 2005-01-24 | 디렉트-할러 아/에스 | 가루약용 흡입기 |
US6207665B1 (en) * | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
US5968938A (en) | 1997-06-18 | 1999-10-19 | Merck & Co., Inc. | Piperazine oxytocin receptor antagonists |
US6287587B2 (en) * | 1997-07-15 | 2001-09-11 | Takeda Chemical Industries, Ltd. | Process for producing sustained-release preparation by in-water drying |
US6211626B1 (en) * | 1997-08-26 | 2001-04-03 | Color Kinetics, Incorporated | Illumination components |
US6193991B1 (en) * | 1997-10-29 | 2001-02-27 | Atul J. Shukla | Biodegradable delivery systems of biologically active substances |
US5892038A (en) * | 1997-12-08 | 1999-04-06 | Pharmacopeia, Inc. | Hydroxy-amino acid amides |
US6084098A (en) | 1999-02-26 | 2000-07-04 | Neurogen Corporation | Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands |
US6613234B2 (en) * | 1998-04-06 | 2003-09-02 | Ciphergen Biosystems, Inc. | Large pore volume composite mineral oxide beads, their preparation and their applications for adsorption and chromatography |
US6534503B1 (en) | 1998-04-28 | 2003-03-18 | Lion Bioscience Ag | Melanocortin receptor-3 ligands to treat sexual dysfunction |
US6127381A (en) * | 1998-04-28 | 2000-10-03 | Basu; Amaresh | Isoquinoline compound melanocortin receptor ligands and methods of using same |
US6284735B1 (en) | 1998-04-28 | 2001-09-04 | Lion Bioscience Ag | HP-3228 and related peptides to treat sexual dysfunction |
US6140354A (en) | 1998-04-29 | 2000-10-31 | Ortho-Mcneil Pharmaceutical, Inc. | N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders |
RU2243215C2 (ru) | 1998-05-11 | 2004-12-27 | Ново Нордиск А/С | Производные пиперидинкарбоновых кислот, фармацевтические композиции, содержащие их, способ стимуляции секреции гормона роста |
US6294534B1 (en) | 1998-06-11 | 2001-09-25 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
EP1085869A4 (en) * | 1998-06-11 | 2001-10-04 | Merck & Co Inc | SPIRO PIPERID DERIVATIVES AS MELANOCORTIN RECEPTORAGONISTS |
DE69943239D1 (de) * | 1998-06-30 | 2011-04-14 | Novo Nordisk As | Verbindungen mit wachstumshormon-freisetzenden eigenschaften |
FR2780649B1 (fr) * | 1998-07-06 | 2001-03-09 | Univ Paris Vii Denis Diderot | Derives de la piperazine pour l'inhibition de la replication du virus de l'immunodeficience humaine |
EP1098977A2 (en) | 1998-07-21 | 2001-05-16 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of body weight disorders, including obesity |
ATE297908T1 (de) | 1998-08-12 | 2005-07-15 | Pfizer Prod Inc | Tace inhibitoren |
WO2000017348A1 (en) * | 1998-09-17 | 2000-03-30 | Hopital Sainte-Justine | G protein-coupled receptor agonists or antagonists |
GB9827500D0 (en) | 1998-12-14 | 1999-02-10 | Wapharm Ab | Compounds for control of eating, growth and body weight |
US6800636B2 (en) * | 1998-12-18 | 2004-10-05 | Schering Corporation | Farnesyl protein transferase inhibitors |
US6372747B1 (en) * | 1998-12-18 | 2002-04-16 | Schering Corporation | Farnesyl protein transferase inhibitors |
US6432959B1 (en) | 1998-12-23 | 2002-08-13 | Schering Corporation | Inhibitors of farnesyl-protein transferase |
AR022204A1 (es) | 1999-01-08 | 2002-09-04 | Norgine Bv | Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende. |
US6294539B1 (en) | 1999-01-19 | 2001-09-25 | Advanced Syntech, Llc | Heterocyclic hydroxamic acid derivatives as MMP inhibitors |
AR022303A1 (es) | 1999-01-22 | 2002-09-04 | Lundbeck & Co As H | Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion |
WO2000051672A1 (en) * | 1999-03-03 | 2000-09-08 | Optinose As | Nasal delivery device |
US6033656A (en) | 1999-05-04 | 2000-03-07 | Sumitomo Chemical Company, Limited | Method of preventing or alleviating mammalian obesity |
US6420369B1 (en) * | 1999-05-24 | 2002-07-16 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating dementia |
AU766191B2 (en) | 1999-06-04 | 2003-10-09 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
US6469006B1 (en) | 1999-06-15 | 2002-10-22 | Bristol-Myers Squibb Company | Antiviral indoleoxoacetyl piperazine derivatives |
US6207699B1 (en) | 1999-06-18 | 2001-03-27 | Richard Brian Rothman | Pharmaceutical combinations for treating obesity and food craving |
US6579968B1 (en) | 1999-06-29 | 2003-06-17 | Palatin Technologies, Inc. | Compositions and methods for treatment of sexual dysfunction |
AU6605800A (en) | 1999-07-16 | 2001-02-05 | Trega Biosciences, Inc. | Melanocortin receptor-3 ligands to treat sexual dysfunction |
US6699873B1 (en) * | 1999-08-04 | 2004-03-02 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
WO2001013112A1 (en) * | 1999-08-12 | 2001-02-22 | Palatin Technologies, Inc. | Melanocortin metallopeptide constructs, combinatorial libraries and applications |
EP1078632A1 (en) | 1999-08-16 | 2001-02-28 | Sanofi-Synthelabo | Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity |
US6774138B2 (en) * | 1999-08-31 | 2004-08-10 | Merck & Co., Inc. | Thiazolyl(pyridyl)ethyne compounds |
US6294525B1 (en) * | 1999-09-01 | 2001-09-25 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
GB9921239D0 (en) | 1999-09-08 | 1999-11-10 | Plant Bioscience Ltd | Plant resistance gene |
ES2264929T3 (es) | 1999-09-08 | 2007-02-01 | Genentech, Inc. | Acidos nucleicos y polipeptidos del factor 19 de crecimiento fibroblastico (fgf-19) y procedimientos de utilizacion para el tratamiento de la obesidad. |
EP1214330A1 (en) | 1999-09-21 | 2002-06-19 | LION Bioscience AG | Benzimidazole derivatives and combinatorial libraries thereof |
CA2388417A1 (en) | 1999-09-22 | 2001-03-29 | Genset | Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases |
US6515122B1 (en) | 1999-09-24 | 2003-02-04 | Lion Bioscience Ag | Tetracyclic benzimidazole derivatives and combinatorial libraries thereof |
US6458789B1 (en) | 1999-09-29 | 2002-10-01 | Lion Bioscience Ag | 2-aminopyridine derivatives and combinatorial libraries thereof |
CA2386750A1 (en) | 1999-10-22 | 2001-05-03 | Merck & Co. Inc. | Pharmaceuticals for treating obesity |
WO2001030808A1 (en) * | 1999-10-27 | 2001-05-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor-ligand binding |
US20030064921A1 (en) * | 1999-10-27 | 2003-04-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor ligand binding and activity |
JP2001184828A (ja) * | 1999-12-21 | 2001-07-06 | Sony Corp | ライナ貼付方法及びライナ貼付装置 |
SE9904738D0 (sv) * | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
DE19963234A1 (de) | 1999-12-27 | 2002-01-24 | Boehringer Ingelheim Pharma | Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
US6462046B2 (en) * | 2000-01-06 | 2002-10-08 | Advanced Syntech, Llc | Heterocycle derivatives as PPAR-gamma agonists |
EP1125579A3 (en) | 2000-01-18 | 2003-01-02 | Pfizer Products Inc. | Uses of agrp-melanocortin receptor binding modulating compounds |
JP2003534240A (ja) * | 2000-01-18 | 2003-11-18 | メルク エンド カムパニー インコーポレーテッド | 強力な選択的メラノコルチン−4受容体アンタゴニストとなる環状ペプチド |
US20030195212A1 (en) | 2000-01-28 | 2003-10-16 | Torbjorn Lundstedt | Novel melanocortin receptor agonists and antagonists |
GB0002059D0 (en) | 2000-01-28 | 2000-03-22 | Melacure Therapeutics Ab | Novel aromatic amines |
AU2001228681A1 (en) | 2000-01-28 | 2001-08-07 | Melacure Therapeutics Ab | Novel aromatic amines and amides acting on the melanocortin receptors |
US6451798B2 (en) | 2000-02-22 | 2002-09-17 | Cv Therapeutics, Inc. | Substituted alkyl piperazine derivatives |
WO2001070347A1 (en) | 2000-03-17 | 2001-09-27 | Fit Express, Inc. | Golf swing conditioner |
EP1136071A3 (en) | 2000-03-22 | 2003-03-26 | Pfizer Products Inc. | Use of glycogen phosphorylase inhibitors |
WO2001070337A1 (en) | 2000-03-23 | 2001-09-27 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
US6458790B2 (en) | 2000-03-23 | 2002-10-01 | Merck & Co., Inc. | Substituted piperidines as melanocortin receptor agonists |
EE200200567A (et) * | 2000-03-31 | 2004-06-15 | Pfizer Products Inc. | Uued piperasiini derivaadid |
AU6497701A (en) | 2000-05-30 | 2001-12-11 | Merck & Co Inc | Melanocortin receptor agonists |
WO2002000259A1 (fr) | 2000-06-27 | 2002-01-03 | Taisho Pharmaceutical Co., Ltd. | Agent therapeutique contre l'anxiete nevrotique ou la depression et derive de piperazine |
BR0111567A (pt) | 2000-06-28 | 2003-05-06 | Pfizer Prod Inc | Ligandos do receptor de melanocortina |
JP2004516239A (ja) | 2000-07-06 | 2004-06-03 | ニューロジェン コーポレイション | メラニン凝集ホルモン受容体リガンド |
US20020032238A1 (en) * | 2000-07-08 | 2002-03-14 | Henning Priepke | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments |
US6191117B1 (en) | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
GB0019359D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel guanidines |
KR100483300B1 (ko) | 2000-08-30 | 2005-04-15 | 에프. 호프만-라 로슈 아게 | 선택적 환형 펩타이드 |
US20020183316A1 (en) | 2000-10-27 | 2002-12-05 | Kevin Pan | Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders |
KR100394083B1 (ko) * | 2000-12-04 | 2003-08-06 | 학교법인 성신학원 | 도파민 d3 및 d4 수용체의 선택적 활성을 지닌 신규4,5-디히드로이소옥사졸릴알킬피페라진 유도체와, 이의제조방법 |
US6612805B2 (en) | 2000-12-05 | 2003-09-02 | Emu Unterwasserpumpen Gmbh | Hydrodynamic machine |
JP2004522720A (ja) | 2000-12-15 | 2004-07-29 | ファイザー・インク | 雄性性的機能障害の処置 |
DE60205727T2 (de) | 2001-01-23 | 2006-06-29 | Eli Lilly And Co., Indianapolis | Piperazin- und piperidinderivate als agonisten des melanocortin-rezeptors |
AU2002238106A1 (en) | 2001-02-13 | 2002-08-28 | Palatin Technologies, Inc. | Melanocortin metallopeptides for treatment of sexual dysfunction |
EP1385506B1 (en) | 2001-02-28 | 2009-05-06 | Merck & Co., Inc. | Acylated piperidine derivates as melanocortin-4 receptor agonists |
US7015235B2 (en) | 2001-02-28 | 2006-03-21 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
EP1236723A1 (en) | 2001-03-01 | 2002-09-04 | Pfizer Products Inc. | Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof |
JP2005506286A (ja) | 2001-03-02 | 2005-03-03 | ブリストル−マイヤーズ スクイブ カンパニー | サイクリック−amp関連疾患の治療を目的としたメラノコルチン受容体アゴニストおよびホスホジエステラーゼ阻害剤の併用投与 |
HUP0303484A2 (hu) * | 2001-03-02 | 2004-01-28 | Bristol-Myers Squibb Company | Melanokortin receptor modulátoraiként hasznos vegyületek és a vegyületeket tartalmazó gyógyszerkészítmények |
US6660858B2 (en) | 2001-03-28 | 2003-12-09 | Lion Bioscience Ag | 2-aminobenzoxazole derivatives and combinatorial libraries thereof |
GB0107751D0 (en) | 2001-03-28 | 2001-05-16 | Pfizer Ltd | Pharmaceutically active compounds |
US7456183B2 (en) | 2001-04-09 | 2008-11-25 | Novartis Vaccines And Diagnostics, Inc. | Guanidino compounds |
US6911447B2 (en) | 2001-04-25 | 2005-06-28 | The Procter & Gamble Company | Melanocortin receptor ligands |
EP1406884A1 (en) | 2001-05-11 | 2004-04-14 | Biovitrum Ab | Arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders |
JP4010951B2 (ja) * | 2001-05-15 | 2007-11-21 | 大正製薬株式会社 | アルギニン誘導体 |
RU2278859C2 (ru) * | 2001-05-15 | 2006-06-27 | Ф.Хоффманн-Ля Рош Аг | Замещенные карбоновыми кислотами оксазоловые производные в качестве ppar-альфа и гамма-активаторов при лечении диабета |
US6593362B2 (en) * | 2001-05-21 | 2003-07-15 | Guilford Pharmaceuticals Inc. | Non-peptidic cyclophilin binding compounds and their use |
CZ20033455A3 (en) * | 2001-06-20 | 2004-06-16 | Pfizer Products Inc. | Novel sulfonic acid derivatives |
US6825198B2 (en) * | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
IL159797A0 (en) | 2001-07-11 | 2004-06-20 | Palatin Technologies Inc | Linear and cyclic melanocortin receptor-specific peptides |
US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
GB0118479D0 (en) | 2001-07-28 | 2001-09-19 | Astrazeneca Ab | Novel compounds |
GB0119172D0 (en) | 2001-08-06 | 2001-09-26 | Melacure Therapeutics Ab | Phenyl pyrrole derivatives |
US7655658B2 (en) * | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
US7732451B2 (en) * | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
CA2462200A1 (en) * | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
US7354923B2 (en) * | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
HUP0202719A3 (en) | 2001-08-21 | 2006-01-30 | Pfizer Prod Inc | Pharmaceutical compositions for the treatment of female sexual dysfunctions |
JP4450365B2 (ja) | 2001-08-28 | 2010-04-14 | シェーリング コーポレイション | 多環式グアニンホスホジエステラーゼv阻害剤 |
AU2002326948A1 (en) * | 2001-09-18 | 2003-04-01 | Bristol-Myers Squibb Company | Piperizinones as modulators of chemokine receptor activity |
US20050069883A1 (en) | 2001-09-26 | 2005-03-31 | Howard Andrew D. | Melanin-concentrating hormone receptor antagonist binding protein |
US20030158209A1 (en) | 2001-10-09 | 2003-08-21 | Neurocrine Biosciences Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
BR0213452A (pt) * | 2001-10-22 | 2004-11-09 | Pfizer Prod Inc | Derivados de piperazina com atividade antagonista receptora de ccr1 |
US7319107B2 (en) | 2001-11-08 | 2008-01-15 | Johnson & Johnson Consumer Companies, Inc. | 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
WO2003040117A1 (en) | 2001-11-08 | 2003-05-15 | Ortho-Mcneil Pharmaceutical Corporation | Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators |
EP1451156A4 (en) | 2001-11-27 | 2005-05-25 | Merck & Co Inc | 4-AMINOQUINOLINE COMPOUNDS |
WO2003055477A1 (en) | 2001-12-21 | 2003-07-10 | 7Tm Pharma A/S | Method for the treatment of mc receptor related disorders with a chelate and/or a chelator |
US20060084657A1 (en) * | 2001-12-21 | 2006-04-20 | Atsuro Nakazato | Piperazine derivative |
JP2005527492A (ja) | 2002-01-23 | 2005-09-15 | イーライ・リリー・アンド・カンパニー | メラノコルチン受容体アゴニスト |
US20030207814A1 (en) | 2002-02-04 | 2003-11-06 | Chiron Corporation | Novel guanidinyl derivatives |
US20030195187A1 (en) | 2002-02-04 | 2003-10-16 | Chiron Corporation | Guanidino compounds |
AU2003219914A1 (en) | 2002-02-25 | 2003-09-09 | Chiron Corporation | Intranasal administration of mc4-r agonists |
AU2003230367A1 (en) | 2002-05-10 | 2003-11-11 | Neurocrine Biosciences, Inc. | Substituted piperazine as melanocortin receptors ligands |
US7160886B2 (en) | 2003-03-03 | 2007-01-09 | Merck & Co., Inc. | Acylated piperazine derivatives as melanocortin-4 receptor agonists |
US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
TW200609219A (en) * | 2004-06-17 | 2006-03-16 | Neurogen Corp | Aryl-substituted piperazine derivatives |
US7834017B2 (en) * | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
US20090076029A1 (en) * | 2007-06-01 | 2009-03-19 | Palatin Technologies, Inc. | Compounds and Methods for Treating Obesity |
-
2002
- 2002-08-12 CA CA002462200A patent/CA2462200A1/en not_active Abandoned
- 2002-08-12 JP JP2003518577A patent/JP2005504043A/ja active Pending
- 2002-08-12 AU AU2002331064A patent/AU2002331064B2/en not_active Ceased
- 2002-08-12 WO PCT/US2002/025574 patent/WO2003013571A1/en active Application Filing
- 2002-08-12 EP EP02768507A patent/EP1425029A4/en not_active Withdrawn
-
2004
- 2004-01-21 US US10/761,889 patent/US7326707B2/en not_active Expired - Fee Related
- 2004-02-10 US US10/776,657 patent/US7189755B2/en not_active Expired - Fee Related
- 2004-02-10 US US10/776,419 patent/US7807678B2/en not_active Expired - Fee Related
-
2007
- 2007-03-01 US US11/680,932 patent/US7601753B2/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010523722A (ja) * | 2007-04-13 | 2010-07-15 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ジアゾ二環式smac模倣物およびその使用 |
US8664212B2 (en) | 2007-04-13 | 2014-03-04 | The Regents Of The University Of Michigan | Diazo bicyclic Smac mimetics and the uses thereof |
Also Published As
Publication number | Publication date |
---|---|
US7189755B2 (en) | 2007-03-13 |
US7601753B2 (en) | 2009-10-13 |
US20040167201A1 (en) | 2004-08-26 |
US7807678B2 (en) | 2010-10-05 |
EP1425029A4 (en) | 2006-06-07 |
AU2002331064B2 (en) | 2007-08-23 |
CA2462200A1 (en) | 2003-02-20 |
US20040171520A1 (en) | 2004-09-02 |
US20040152134A1 (en) | 2004-08-05 |
US7326707B2 (en) | 2008-02-05 |
EP1425029A1 (en) | 2004-06-09 |
US20070155670A1 (en) | 2007-07-05 |
WO2003013571A1 (en) | 2003-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005504043A (ja) | 生物学的に活性な金属ペプチド類のペプチド模倣体類 | |
AU2002331064A1 (en) | Peptidomimetics of biologically active metallopeptides | |
Jamieson et al. | Peptide scanning for studying structure‐activity relationships in drug discovery | |
CN100384819C (zh) | 与细胞凋亡蛋白抑制剂结合的smac蛋白的肽抑制剂 | |
Williams et al. | 1-(((7, 7-Dimethyl-2 (S)-(2 (S)-amino-4-(methylsulfonyl) butyramido) bicyclo [2.2. 1] heptan-1 (S)-yl) methyl) sulfonyl)-4-(2-methylphenyl) piperazine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor | |
Cai et al. | Biological and conformational study of β‐substituted prolines in MT‐II template: steric effects leading to human MC5 receptor selectivity | |
Sun et al. | Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics | |
US20040224957A1 (en) | Melanocortin receptor-specific compounds | |
BRPI0617751A2 (pt) | compostos de ligação do domìnio iap bir | |
AU1570292A (en) | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same | |
Pierry et al. | Fluorinated pseudopeptide analogues of the neuropeptide 26RFa: Synthesis, biological, and structural studies | |
US7354923B2 (en) | Piperazine melanocortin-specific compounds | |
TW415945B (en) | Inhibitors of prenyl transferases | |
JPH0368597A (ja) | コレシストキニンレセプターリガンドおよびその製法 | |
Pluym et al. | Application of the Guanidine–Acylguanidine Bioisosteric Approach to Argininamide‐Type NPY Y2 Receptor Antagonists | |
US7385025B2 (en) | Metallopeptide compounds | |
Bourguet et al. | Benzophenone semicarbazone protection strategy for synthesis of aza‐glycine containing aza‐peptides | |
Mollica et al. | Synthesis and biological evaluation of new biphalin analogues with non-hydrazine linkers | |
US20060104907A1 (en) | Biologically potent analogues of the Dmt-Tic pharmacophore and methods of use | |
Fry et al. | Utilizing peptide structures as keys for unlocking challenging targets | |
Shakeri et al. | Synthesis, molecular modeling and functional evaluation of a GnRH antagonist | |
Balboni et al. | Further studies on the effect of lysine at the C-terminus of the Dmt-Tic opioid pharmacophore | |
ZA200509683B (en) | Melanocortin receptor-specific compounds | |
SA517381865B1 (ar) | بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين | |
KR20020038400A (ko) | 디썰파이드로 결합되는 환펩타이드형 화합물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050728 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080617 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080916 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090825 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100216 |